A citation-based method for searching scientific literature

Jai N Patel. Pharmacogenet Genomics 2015
Times Cited: 17







List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pharmacogenomics in oncology care.
Kelly K Filipski, Leah E Mechanic, Rochelle Long, Andrew N Freedman. Front Genet 2014
21
17


Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
614
17



Pharmacogenetics of cancer drugs.
Daniel L Hertz, James Rae. Annu Rev Med 2015
28
17

Precision medicine--personalized, problematic, and promising.
J Larry Jameson, Dan L Longo. N Engl J Med 2015
523
11

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
11

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
K E Caudle, C F Thorn, T E Klein, J J Swen, H L McLeod, R B Diasio, M Schwab. Clin Pharmacol Ther 2013
235
11

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Adam M Lee, Qian Shi, Emily Pavey, Steven R Alberts, Daniel J Sargent, Frank A Sinicrope, Jeffrey L Berenberg, Richard M Goldberg, Robert B Diasio. J Natl Cancer Inst 2014
103
11

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
11

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Felix W Frueh, Shashi Amur, Padmaja Mummaneni, Robert S Epstein, Ronald E Aubert, Teresa M DeLuca, Robert R Verbrugge, Gilbert J Burckart, Lawrence J Lesko. Pharmacotherapy 2008
180
11

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer.
Hyo Sook Han, Isildinha M Reis, Wei Zhao, Katsumasa Kuroi, Masakazu Toi, Eiji Suzuki, Rachel Syme, Louis Chow, Adrian Y S Yip, Stefan Glück. Eur J Cancer 2011
34
11

Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
Ana E Rodríguez-Vicente, Eva Lumbreras, Jesus M Hernández, Miguel Martín, Antonio Calles, Carlos López Otín, Salvador Martín Algarra, David Páez, Miquel Taron. Drug Metab Pers Ther 2016
13
15

The path to personalized medicine.
Margaret A Hamburg, Francis S Collins. N Engl J Med 2010
984
11

Cancer pharmacogenomics: strategies and challenges.
Heather E Wheeler, Michael L Maitland, M Eileen Dolan, Nancy J Cox, Mark J Ratain. Nat Rev Genet 2013
138
11

Somatic pharmacogenomics in cancer.
O N Ikediobi. Pharmacogenomics J 2008
21
11

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets,[...]. Nature 2010
11

Population-based differences in treatment outcome following anticancer drug therapies.
Brigette By Ma, Edwin P Hui, Tony Sk Mok. Lancet Oncol 2010
99
11

Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
Jamie L Renbarger, Kevin C McCammack, Caroline E Rouse, Stephen D Hall. Pediatr Blood Cancer 2008
86
11

Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America.
Luis Abel Quinones, Maria Alejandra Lavanderos, Juan Pablo Cayun, Elena Garcia-Martin, Jose Augusto Agundez, Dante Daniel Caceres, Angela Margarita Roco, Jorge E Morales, Luisa Herrera, Gonzalo Encina,[...]. Curr Drug Metab 2014
20
11

A global reference for human genetic variation.
Adam Auton, Lisa D Brooks, Richard M Durbin, Erik P Garrison, Hyun Min Kang, Jan O Korbel, Jonathan L Marchini, Shane McCarthy, Gil A McVean, Gonçalo R Abecasis. Nature 2015
11

Genomics is failing on diversity.
Alice B Popejoy, Stephanie M Fullerton. Nature 2016
643
11

State of Art of Cancer Pharmacogenomics in Latin American Populations.
Andrés López-Cortés, Santiago Guerrero, María Ana Redal, Angel Tito Alvarado, Luis Abel Quiñones. Int J Mol Sci 2017
13
15

DNA methylation-based variation between human populations.
Farzeen Kader, Meenu Ghai. Mol Genet Genomics 2017
50
11


Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
11


Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.
S L Van Driest, Y Shi, E A Bowton, J S Schildcrout, J F Peterson, J Pulley, J C Denny, D M Roden. Clin Pharmacol Ther 2014
177
11

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
276
11

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.
Simona Volpi, Carol J Bult, Rex L Chisholm, Patricia A Deverka, Geoffrey S Ginsburg, Howard J Jacob, Melpomeni Kasapi, Howard L McLeod, Dan M Roden, Marc S Williams,[...]. Clin Pharmacol Ther 2018
66
11

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
406
11

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Mary V Relling, Matthias Schwab, Michelle Whirl-Carrillo, Guilherme Suarez-Kurtz, Ching-Hon Pui, Charles M Stein, Ann M Moyer, William E Evans, Teri E Klein, Federico Guillermo Antillon-Klussmann,[...]. Clin Pharmacol Ther 2019
228
11


Resistance to chemotherapy: patient variability and cellular heterogeneity.
David A Kessler, Robert H Austin, Herbert Levine. Cancer Res 2014
31
5

Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.
Angela Roco, Luis Quiñones, José A G Agúndez, Elena García-Martín, Valentina Squicciarini, Carla Miranda, Joselyn Garay, Nancy Farfán, Iván Saavedra, Dante Cáceres,[...]. Front Genet 2012
43
5



Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs.
José A G Agúndez, Gara Esguevillas, Gemma Amo, Elena García-Martín. Front Pharmacol 2014
4
25

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
Edward M Newman, Robert J Morgan, Shivaani Kummar, Jan H Beumer, M Suzette Blanchard, Christopher Ruel, Anthony B El-Khoueiry, Mary I Carroll, Jessie M Hou, Chun Li,[...]. Cancer Chemother Pharmacol 2015
28
5

Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
Benjamin Izar, Julia Rotow, Justin Gainor, Jeffrey Clark, Bruce Chabner. Pharmacol Rev 2013
24
5

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
Angela Roco, Juan Cayún, Stephania Contreras, Jana Stojanova, Luis Quiñones. Front Genet 2014
22
5

Clinical association between pharmacogenomics and adverse drug reactions.
Zhi-Wei Zhou, Xiao-Wu Chen, Kevin B Sneed, Yin-Xue Yang, Xueji Zhang, Zhi-Xu He, Kevin Chow, Tianxin Yang, Wei Duan, Shu-Feng Zhou. Drugs 2015
27
5

Pharmacogenomics: playing the odds.
Amy Maxmen. Nature 2011
3
33

Moving towards individualized medicine with pharmacogenomics.
William E Evans, Mary V Relling. Nature 2004
472
5

[Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
Luis Quiñones S, Mario Rosero P, Angela Roco A, Iván Moreno T, Jaime Sasso A, Nelson Varela F, Dante Cáceres L, Iván Saavedra S. Rev Med Chil 2008
3
33

Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer.
David M Zocche, Carolina Ramirez, Fernando M Fontao, Lucas D Costa, María A Redal. Front Genet 2015
15
6

Prediction of individual response to anticancer therapy: historical and future perspectives.
Florian T Unger, Irene Witte, Kerstin A David. Cell Mol Life Sci 2015
32
5

Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Lisette Binkhorst, Ron H J Mathijssen, Agnes Jager, Teun van Gelder. Cancer Treat Rev 2015
61
5

Cytochrome P450 gene polymorphism and cancer.
Jose A G Agundez. Curr Drug Metab 2004
220
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.